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Overdose deaths: a very high burden of premature 
preventable deaths
Over 8 200 deaths involving one or more illicit drugs 
were reported in 2017 in the European Union. This 
estimate exceeds 9 400 deaths when Norway and 
Turkey are included. Males account for four-fifths of the 
drug-induced deaths. Most of the deaths were 
premature, affecting people in their thirties and forties.
Opioids: the main driver of fatal overdoses in Europe
 § Opioids, often heroin, are involved in between eight 
and nine out of every 10 drug-induced deaths 
reported in Europe, although this is not true for all 
countries.
 § Opioids used in substitution treatment are also 
commonly found in post-mortem analysis in some 
countries.
 § Deaths related to medications, such as oxycodone 
and tramadol, are also reported.
 § Deaths associated with fentanyl, its analogues are 
probably underestimated, and outbreaks of deaths 
related to these substances have been reported.
Stimulants and benzodiazepines involved in many 
deaths
 § Post-mortem toxicology analyses of overdose cases 
suggest that in most cases, multiple drug toxicity is 
implicated.
 § Overall, cocaine is reported in an increasing number 
of deaths. Increased cocaine injection is also 
reported in several countries.
 § Synthetic cannabinoids were involved in the majority 
of drug-induced deaths reported in Turkey in 2017.
 § Fake medicines, diverted medicines and new 
benzodiazepines are related to an increasing 
proportion of drug-related deaths in some countries. 
Benzodiazepines are causing particular concern in 
Scotland (UK), where they were implicated in more 
than half of the reported drug-related deaths in 2017, 
with recent increases driven mainly by deaths 
involving new benzodiazepines such as etizolam.
High overall mortality among drug users
Seven countries reported new data from mortality 
cohort studies among high-risk drug users:
 § Findings suggest that high-risk drug users are three 
to seven times more likely to die than their peers of 
the same age and gender in the general population.
 § The most frequently reported causes of death include 
overdose, HIV/AIDS, other infections, liver disease, 
cancer, respiratory disease and cardiovascular 
disease.
 § The proportion of deaths due to overdose is likely to 
be underestimated.
Responding to drug-related deaths
 § Coverage and diversity of responses to drug-related 
deaths vary between and within countries.
 § Updates provided on drug consumption rooms and 
take-home naloxone programmes indicate the 
expansion of these responses in countries across 
Europe in 2018.
 § While the evidence base for their effectiveness is 
growing, more research is needed on these and other 
responses.
Implications for public health and for monitoring
 § There is an ongoing need to improve the 
epidemiology of drug-related deaths — from 
a toxicology perspective, in particular — in order to 
get more accurate and informative figures in Europe.
 § Further implementation of cohort and linkage studies 
is needed and can be attained with relatively little 
investment.
 § Additional sources of information offer timelier 
data — important for early identification of threats — 
and may be triangulated. These include open source 
information monitoring and data from acute 
intoxications presented at hospital emergency units.
At a glance: a summary of key points
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I Introduction and objective of this report
This publication provides an update on drug-related 
deaths in Europe. It is primarily based on presentations 
and discussions held at a two-day annual meeting of the 
EMCDDA expert network on drug-related deaths in Lisbon 
on 8 and 9 November 2018. The meeting gathered experts 
and representatives from more than 40 countries, and 
provided a platform for the presentation of new trends and 
analyses on drug-induced deaths and overall mortality 
among high-risk drug users in Europe and beyond.
Drug-related mortality is a complex phenomenon. The 
EMCDDA has defined a drug-related death and mortality 
(DRD) epidemiological indicator with two complementary 
components: (i) national, population-based statistics on 
deaths directly attributable to the use of drugs (drug-
induced deaths, also known as poisonings or overdoses) 
and (ii) estimations of the overall and cause-specific 
mortality among high-risk drug users. These two 
components, based on common methodologies, can fulfil 
several public health objectives, notably as an indicator of 
the overall health impact of drug use. The indicator, when 
interpreted in conjunction with other drug indicators, plays 
an essential role in identifying changes and threats, 
informing policy decisions and measuring the impact of 
responses. Taking stock of the latest data on drug-related 
deaths in Europe, this report presents important highlights 
from the presentations and discussions that took place at 
the expert meeting. Some of the information outlined here 
is necessarily preliminary.
I  Overdose deaths in Europe: comparisons and causes
It is estimated that at least 8 238 overdose deaths occurred 
in the European Union in 2017. This rises to an estimated 
9 461 deaths if Norway and Turkey are included, 
representing a stable figure (an increase of 0.7 %) compared 
with the revised 2016 figure of 9 397. These overall 
numbers must be understood as underestimations, as there 
are limitations to drug-induced deaths data, particularly to 
European cumulative totals (see the box ‘Monitoring 
drug-induced deaths’, page 6). As in previous years, the 
United Kingdom (34 %) and Germany (13 %) together 
account for around half of the EU total. This relates partly to 
the size of the at-risk populations in these countries, but 
also to the under-reporting in some other countries.
The mortality rate due to drug overdoses in Europe in 2017 
is estimated at 22.6 deaths per million population aged 
15-64 (1), but this varies across countries, with higher rates 
being observed in countries in the north of Europe 
(Figure 1). Nevertheless, drug overdose continues to be 
a major cause of premature death among people who use 
(1) This age range is selected for computation of mortality rate for reasons 
of comparability across indicators and datasets. 
FIGURE 1
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Note: Data for 2017 or last year available. Only countries accounting for more than 1 % of the deaths are named in the chart.
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drugs in Europe, predominantly affecting males: 
35.8 cases per million males aged 15-64 years, which is 
almost four times that among females (9.3 cases per 
million females aged 15-64 years). Furthermore, it was 
estimated that drug overdoses accounted for 4 % of all 
deaths among 15- to 39-year-olds in Europe (EMCDDA, 
2011).
l Overdose deaths in North America
The United States has experienced three cumulative 
waves of opioid crises over the past two decades: the first 
was mostly related to prescription painkillers, the second 
to heroin and the third to highly potent synthetic opioids 
(Figure 2).
In 2017, there were 70 237 drug overdose deaths reported 
in the United States (Hedegaard et al., 2018). This 
translates into an age-adjusted rate of drug overdose 
deaths that year of 217 per million (about 10 times the EU 
rate), and represents an increase of 9.6 % on the previous 
year (198 per million). Whereas this continued increase 
was primarily fuelled by opioids, the age-adjusted rate of 
drug overdose deaths involving synthetic opioids other 
than methadone (drugs such as fentanyl, fentanyl 
analogues and tramadol) increased by 45 % between 2016 
and 2017, from 62 to 90 overdose deaths per million 
(Hedegaard et al., 2018). According to the provisional data 
for the 12 months ending in August 2018, the number of 
deaths in the United States is estimated to have remained 
stable at 70 424 (Ahmad et al., 2019; Hedegaard et al., 
2018).
Meanwhile an opioid crisis is developing in Canada, driven 
by both illicit and prescription opioid misuse, with fentanyl 
and its analogues compounding the epidemic. In 2017 
there were 3 998 apparent opioid-related deaths, a death 
rate of 109 per million population — approximately five 
times the EU rate. Provisional data from January to June 
2018 suggest a small increase to 112 deaths per million 
population (Special Advisory Committee on the Epidemic 
of Opioid Overdoses, 2018).
l Demographic characteristics
Demographic analysis provides insight into where the 
current burden of deaths lies, and into implications for 
responses. Whereas an estimated 78 % of the reported 
deaths are of males, the proportion of women has recently 
increased, for example in Scotland (United Kingdom). 
The EMCDDA defines drug-induced deaths as those 
‘happening shortly after consumption of one or more 
illicit psychoactive drug, and directly related to this 
consumption’, and these often occur in the context of 
the co-use of other substances such as alcohol or 
psychoactive medicines (EMCDDA, 2010). Monitoring 
drug-induced deaths is one of two components of the 
DRD epidemiological indicator. It requires the existence 
of good-quality information sources, in particular 
general mortality registries and/or special mortality 
registries. The EMCDDA protocols define operative 
criteria for the extraction of relevant deaths from these 
registries. Extracting from both sources allows cross-
validation of the data, but some countries have data 
available from only one source.
Although most countries are able to fully apply the 
operative criteria for the extraction of relevant deaths, 
there are important limitations to drug-induced deaths 
data, particularly to European cumulative totals. Of 
importance are differences between (and within) 
countries with regard to the identification, certification 
of the cause of death, coding and reporting of the 
number of drug-induced deaths (England, 2017a). This 
relates to the quality and frequency of post-mortem 
investigations, the availability of this information for the 
determination of the cause of death, the codification 
system used and the quality of codification, and the 
coverage and quality of the overall reporting system 
(EMCDDA, 2017b; England, 2017b,c). There are also 
different levels of forensic laboratory capacities, and 
different standard procedures for post-mortem 
toxicological investigation of suspected drug-induced 
deaths (EMCDDA, 2019; Leifman, 2017). These factors 
have an impact on the sensitivity of the analysis, and 
hence on the comparability of the data within and 
across countries. Caution is thus advised when 
interpreting and comparing drug-induced deaths data 
over time and between countries.
The quality of the DRD indicator information depends on 
the quality of its sources, and will increase with 
improvement of post-mortem investigations and the full 
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Males accounted for 70 % of the drug-induced deaths 
there in 2017 and, comparing the annual average for 
2013-17 with that for 2003-07, the percentage increase in 
the number of drug-induced deaths was greater for 
females (203 %) than for males (68 %) (National Records 
Scotland, 2018).
There is an ongoing increase in the reported number of 
overdose deaths among older age groups. Older people 
represent a large proportion of all drug-induced deaths in 
west European countries (Figure 3). That reflects the 
ageing nature of Europe’s opioid-using population in most 
countries, and suggests that older high-risk drug users 
may be at greatest risk of drug overdose death (Pierce et 
al., 2018).
In 2017, the overall mean age at death due to overdose was 
39 years, compared with 36 in 2012, and the highest 
FIGURE 2
Drivers of the upward trend in drug-related deaths in the United States, 1999-2017















ird wave: synthetic 
opioids other than
methadone, from 2014
Note: Age-adjusted overdose death rates. The European trend for all drug-induced deaths rates per million population aged 15-64 is presented for comparison.
Sources: National Center for Health Statistics, National Vital Statistics System, Mortality; EMCDDA. Both adapted by the EMCDDA.
FIGURE 3
Proportion of drug-induced deaths in people aged 40 years or more (left) and  
aged less than 25 years (right), 2017 or last data available
Aged 40 years and older
>50 %40-50 %<40 % No data
Under 25 years of age
No data>10 %5-10 %<5 %
8
Drug-related deaths and mortality in  Europe
mortality rates were found among those aged 35 to 
39 years, with 57 deaths reported per million males and 13 
per million females in this age group. Some countries fall 
outside this general characterisation. Turkey, for instance, 
has a younger drug-using population (possibly reflecting 
its overall younger general population), which is mostly 
characterised by non-opioid drug use (see ‘Synthetic 
cannabinoids’, page 12). The highest drug-induced 
mortality rates in Turkey occur among males aged 25 to 29 
and females aged 20 to 24. Overall in Europe, 247 drug-
induced deaths among people aged less than 21 years 
have been reported in the most recent year for which data 
are available (2017 for 20 countries, 2016 for six, 2015 for 
two and 2014 for one).
In England, as part of a drug-induced deaths inquiry, 
a ‘deep dive’ study on a sample of drug misuse deaths was 
commissioned. The most commonly observed 
characteristics included, although not necessarily in 
combination, being white, single or divorced, unemployed, 
male, and living alone. In Italy, an open source information-
monitoring system has observed that an overwhelming 
majority of the deaths occurred after the person had used 
drugs alone. This has important implications for public 
health responses. The ‘deep dive’ study in England 
resulted in recommendations for clinical practice and 
responses to specific risk factors, such as harm reduction 
messages on using drugs while alone or consuming drugs 
alongside alcohol (ONS, 2018).
l Opioids
Heroin
It is important to bear in mind that most drug-induced 
deaths are attributed to multiple drug toxicity. Opioids, 
mostly heroin, are involved in most of the drug-induced 
deaths reported in Europe. Heroin, in particular, claims 
a high toll of deaths in a number of countries. In England 
and Wales (UK), heroin/morphine is mentioned in 1 164 
deaths, or 47 % of the cases, registered in 2017 (ONS, 
2018). In France, it is mentioned in 131 deaths recorded in 
the special mortality register, or 40 % of the cases with 
information available. In Germany, heroin is recorded in 
409 deaths reported by the police, or 32 % of cases, and in 
Norway it is mentioned in 49 deaths reported in the 
general mortality register in 2017, or 20 % of the cases.
In England and Wales (UK), the most recent data on opioid 
deaths show that heroin continues to be the most 
commonly mentioned opioid (Figure 4). Detailed data 
about opioid  deaths occurring in 2016 show that heroin 
was implicated in 69 % of the deaths among males 
(compared with 55 % among females). The mean age at 
the time of death from heroin overdose was 42 years 
(44 years for opioid-related deaths as a whole). Around 
nine in 10 heroin deaths were recorded as accidental, and 
one tenth as with a suicidal intent. In Scotland, heroin was 
implicated in, or potentially contributed to, half of all 
drug-induced deaths in 2017 (470 deaths, 50 %).
In England, Public Health England’s inquiry into increases 
in drug-induced deaths highlighted changes in heroin 
purity and an ageing of the drug-using population with 
multiple co-morbidities as the principal factors behind the 
increases in the number of heroin-related deaths over the 
previous years. Mortality cohort studies in England and in 
Scotland have also highlighted higher methadone-specific 
death rates in older methadone clients (Gao et al., 2016; 
Pierce et al., 2018), and a narrowing of risk between men 
and women with age (Pierce et al., 2015).
Non-heroin opioids
Some countries now report that opioids other than heroin 
are associated with a high number and sometimes an 
increasing share of drug-induced deaths.
FIGURE 4
Overall trend in registrations of opioid deaths where 
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 (1) Not from compound formulation.
Source: ONS data presented by Martin White at the DRD expert meeting.
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In France, according to the latest available data (2016) 
from the special mortality register, opioids were present in 
80 % of all drug-induced deaths. Methadone was 
associated with four out of 10 opioid-related cases, 
a slightly higher proportion than heroin. This continues 
a pattern observed for several years.
In Norway, a shift has been observed in the relative 
importance of different opioids, with heroin now identified 
as the main intoxicant involved in a fifth (20 %) of the 
overdose deaths in 2017, compared with around half of the 
deaths (49 %) in 2006 (Figure 5). Methadone (22 %) and 
the category ‘synthetic opioids including fentanyl and 
buprenorphine’ (17 %) are commonly identified as a main 
intoxicant in post-mortem examinations. These changes 
are concurrent with significant shifts in the dispensing of 
prescribed opioids in Norway over the last decade (Muller 
et al., 2019). There has been a scaling-up of buprenorphine 
prescription for the management of opioid dependence, 
and an increasing trend in the prescription of other opioids 
(namely tramadol and oxycodone) in the general 
population over the last 10 years. For example, oxycodone 
was prescribed to 5 200 males in 2006, compared with 
19 700 in 2016 (a 279 % increase), and tramadol was 
prescribed to 29 600 males in 2006, compared with 
94 200 in 2016 (a 218 % increase).
Tramadol is an opioid associated with a significant number 
of deaths in Europe. At least 300 drug-induced deaths 
were reported in 2017 in which tramadol was either 
present or implicated: most notably 185 in England and 
Wales (10 % of all opioid-related deaths where the opioid 
was known), 40 in Spain, 37 in France and 20 in Finland. In 
Sweden, concerns have been raised regarding its use 
among young people.
Tramadol is often used in combination with other drugs, 
and it is therefore difficult to assess its contribution to 
deaths where it is recorded. In addition, the presence of 
tramadol (and other substances) might be underestimated, 
as it might not be systematically looked for, or not reported 
when found. Several countries, including France, the 
United Kingdom and Norway, report an increase in the 
prescription of this and of other opioids.
Fentanyl analogues
More than 30 fentanyl analogues have been detected and 
reported to the EMCDDA since 2012. Available from the 
surface web, from the darknet and at street level, they are 
used to make fake medicines or sold as ‘legal’ 
replacements to illicit opioids (Figure 6). They are also 
found in, or sold as, heroin, other illicit opioids and cocaine. 
Novel dosage forms such as nasal sprays and e-liquids 
have emerged in recent years. Fentanyl and its analogues 
can cause rapid onset of life-threatening respiratory 
depression, and their appearance on the drug market has 
been associated with increases in poisonings. 
Cyclopropylfentanyl, carfentanil and acryloylfentanyl, in 
particular, have been associated with large numbers of 
deaths: 78, 61 and 47 deaths, respectively, at the time of 
their risk assessments (EMCDDA, 2017a, 2018a,b). While 
illicit fentanyl and its analogues have been associated with 
deaths in Europe, there is some evidence of diversion of 
medicinal fentanyl (e.g. patches) to illicit markets, and this 
might also be associated with deaths but to a much lesser 
extent.
In England, in the spring of 2017, intelligence from post-
mortem results and drug seizures suggested that fentanyl 
and its analogues had been introduced into the heroin 
supply in the north of the country. Public Health England 
issued an alert at the end of April 2017 advising (i) on the 
availability of, and harms from, heroin that had been mixed 
with fentanyl or carfentanil, (ii) that warnings be cascaded 
and (iii) of the naloxone dosing regime in the event of an 
FIGURE 5
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(1) Including morphine, codeine and oxycodone.
(2) Including fentanyl and buprenorphine.
(3) According to the EMCDDA denition.
Other semi-synthetic opioids (1) Methadone Heroin 
Synthetic opioids (2) Stimulants
Other drugs
F-diagnoses (3)
Note: F-diagnosis refers to mental and behavioural disorders due to 
psychoactive substance use, without more specific information about the 
drugs involved. 
Source: Data from Norwegian Institute of Public Health 2019, presented by 
Thomas Clausen at the DRD expert meeting.
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overdose. Around the same time, police and the National 
Crime Agency disrupted a laboratory that could have been 
the site for processing and mixing fentanyl and other 
analogues, and they sought to raise awareness. Official 
data from the Office for National Statistics, analysed by 
Public Health England, indicate that around 26 deaths 
registered in 2017 appeared to fit the pattern of the 
incident (Figure 7). Most of the deaths were concentrated 
in urban areas of Yorkshire and the Humber (around where 
the lab was based), with 18 deaths recorded (a rate of 6.8 
per million population aged 15-64, and 6.5 % of all drug 
misuse deaths in the region). There were five cases in the 
North East (a rate of 3.0 per million population aged 15-64, 
and 2.4 % of all drug misuse deaths). In the other regions 
put together, three cases were recorded. The 26 deaths 
are only those on which the inquests have currently 
concluded; there will be more that are yet to be registered 
and will appear in the data for 2018 when these are 
released by the Office for National Statistics (even though 
all the deaths occurred in 2017).
In Sweden, data from forensic analyses show that there 
has been a major decrease in the reported number of 
deaths related to fentanyl analogues, with 11 reported in 
2018 compared with 101 in the previous year. In 2017, 
there were 30 cases related to fentanyl and 107 related to 
heroin. The drop in 2018 may be related to the number of 
fentanyl analogues that were classified as narcotic drugs 
or ‘goods dangerous to health’ over the previous year 
(Figure 8). That classification resulted in new possibilities 
of prosecuting those who sell not-yet-classified new 
psychoactive substances (NPS), which influenced supply. 
Recent evidence suggests that the classified fentanyl 
analogues disappeared from the open web shops in 
Sweden.
FIGURE 6
Fentanyl analogues: fake medicines (Xanax), nasal sprays and powder containing fentanyl analogues, detected in Europe
Note: Fake Xanax tablets containing cyclopropylfentanyl (copyright Swedish Police). Unlabelled nasal sprays containing acryloylfentanyl (copyright Anders 
Helander, Karolinska Institutet, Stockholm). A ziplock bag found inside a foil packet, containing carfentanil as a white powder (copyright Norwegian National 
Criminal Investigation Service).
FIGURE 7
Fentanyl-related incidents in England (UK) in 2017: 














Number of cases per region 
Source: Martin White, DRD expert meeting
Note: Large urban centres are shown in green.
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l Stimulants
Cocaine
Cocaine use has important health implications, particularly 
when the drug is consumed with other substances or 
when injected, alone or in combination with heroin 
(EMCDDA, 2018d). Cocaine use is also associated with 
increased risk of blood-borne and sexually transmitted 
infection, through increased frequency of injecting (when 
sharing and re-using injection equipment), crack pipe 
sharing and increased libido.
In recent years, the European drug market has been 
experiencing an increase in both availability and purity of 
cocaine. A rise in powder cocaine injection and in the use 
and injection of crack-cocaine has also been noted in 
some countries. These developments have resulted in 
significant public health impacts, with more cocaine-
related hospital emergencies and deaths as well as HIV 
outbreaks linked with cocaine use reported in Europe over 
the past few years (EMCDDA, 2018d). In Scotland, for 
instance, there has been a marked increase in recent years 
in the number of deaths with cocaine present across the 
country, and in the prevalence of cocaine injecting as 
reported by clients of the needle and syringe exchange 
services (Figure 9).
In Luxembourg, the prevalence of cocaine consumption 
among high-risk drug users has been increasing over time, 
as evidenced in data from drug consumption rooms in the 
country: 28 % of the clients consumed cocaine in 2018, 
compared with 4 % in 2013 (Figure 10). There was 
a similar increase for ‘cocaine mixture’ (typically cocaine 
mixed with heroin): 12 % of the drug consumption room 
clients reported its use in 2018, compared with 3 % in 
2013. In 2018, those who consumed cocaine in drug 
consumption rooms did so mostly by snorting (51 %) or 
injecting (46 %).
FIGURE 8
Deaths related to fentanyl, fentanyl analogues and heroin 
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Source: National Board of Forensic Medicine (2019), data from forensic 
analyses presented by Mimmi Eriksson Tinghog at the DRD expert meeting, 
adapted by the EMCDDA.
FIGURE 9
Deaths with cocaine present in Scotland (UK) and 





















2010 2011 2012 2013 2014 20162015 2017 2018
Sources: National Records of Scotland (NRS); Needle Exchange Surveil-
lance Initiative (NESI). Reported by Andrew McAuley and Roy Robertson. 
Presented by Roy Robertson at DRD expert meeting and adapted by the 
EMCDDA.
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Synthetic cannabinoids
Synthetic cannabinoids are being used in Europe among 
young people and vulnerable groups, including prisoners, 
homeless people and opioid injectors. The effects of 
synthetic cannabinoids often appear more pronounced 
and severe than those of cannabis, and can include 
symptoms such as tachycardia, delirium, seizures, 
psychosis and anxiety. Worldwide, an increase in severe 
poisonings and deaths associated with these substances 
has been observed with, at times, large outbreaks of mass 
poisonings overwhelming emergency responders and 
emergency rooms.
In Turkey, more than 550 deaths related to synthetic 
cannabinoids were reported in 2017, four times the 
number reported in 2015. Synthetic cannabinoids are 
associated with the majority of drug-induced deaths in 
Turkey (Figure 11), in contrast with the other countries in 
Europe.
Deaths related to synthetic cannabinoids have also been 
reported by other countries, though to a far lesser extent. 
For instance, 29 deaths associated with MDMB-CHMICA 
were reported by five EU Member States and Norway by 
the time this substance was risk-assessed (EMCDDA, 
2016). Particular care should be taken when comparing 
NPS-related deaths between countries and over time, as 
there may be considerable under-ascertainment and 
under-reporting of these cases.
l Benzodiazepines
Benzodiazepines are a family of psychoactive medicines 
prescribed commonly for anxiety disorders, insomnia, 
muscle spasms and seizures. They are a risk factor for 
fatal drug overdose because of their depressant effect on 
the central nervous system, which can potentiate the 
respiratory depression effect of heroin and other opioids. 
Whereas deaths related to benzodiazepines alone do not 
fall within the EMCDDA definition of overdose death, 
benzodiazepines are often identified in post-mortem 
toxicology examinations of deaths related to illicit drugs.
In addition to prescription benzodiazepines, new 
psychoactive substances belonging to the benzodiazepine 
class, which are not controlled under international drug 
control laws, are available on the drug market in Europe. 
Some of these ‘new benzodiazepines’ are sold as fake 
versions of commonly prescribed anti-anxiety medicines 
such as alprazolam (Xanax) and diazepam (Valium), 
making use of existing distribution networks in the illicit 
drug market. Others are sold online, sometimes under their 
own names or marketed as ‘legal’ versions of authorised 
medicines.
FIGURE 10














Source: Michel Yegles, DRD expert meeting.
FIGURE 11
Opioid-related, non-opioid-related and synthetic 




















Source: Bulent Sam, DRD expert meeting.
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In Scotland, the prevalence of benzodiazepine-related 
deaths has increased in recent years; in 2017, 
benzodiazepines were implicated in more than half of the 
934 drug-induced deaths recorded. A number of 
benzodiazepines are sold as ‘street Valium’ and, while they 
may have a similar appearance to Valium tablets, some 
were found to contain diclazepam, other new 
benzodiazepines, a mixture of etizolam and the synthetic 
opioid U-47,700, or U-47,700 on its own — increasing the 
risk of accidental overdose. Etizolam is related to the 
benzodiazepines and has similar effects. It is readily 
available online, and is associated with an increasing 
number of deaths (Figure 12).
l  Overall mortality: insights from cohort studies
The World Health Organization (WHO) estimates that 
450 000 deaths occurred in 2015 as a result of drug use 
(WHO, 2018). Of those, 167 000 were directly attributed to 
the use of drugs, that is, drug-induced deaths or 
FIGURE 12
Deaths where benzodiazepines were implicated in 
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Etizolam Diazepam Alprazolam Phenazepam
Diclazepam TemazepamDelorazepam
Source: National Records of Scotland (NRS) — reported by Andrew McAuley 
and Roy Robertson. Presented by Roy Robertson at the DRD expert meeting.
Monitoring overall mortality among high-risk drug users is 
the second component of the EMCDDA DRD 
epidemiological indicator. The overall or ‘all-cause’ mortality 
among high-risk drug users is investigated by means of 
cohort studies, which link records from death registers with 
records of individuals — typically from treatment 
registers — who are or have been using drugs. In this way, it 
is possible to check the vital status of the individuals who 
enrolled in treatment at some point. Follow-up cohort 
studies also allow measurements of behaviour over time, for 
example the duration of treatment and interruptions, if any. 
‘Linkage studies’ connect records of drug users and 
mortality registers but do not collect information on 
subsequent drug use or treatment history after enrolment.
Although their results might not be readily generalisable to 
other populations of high-risk drug users, mortality cohort 
studies are an important contribution to a better 
understanding of drug-related deaths. They determine 
overall mortality rates among high-risk drug users, estimate 
their excess mortality risk compared with the general 
population, and give information about cause-specific 
mortality such as from hepatitis, liver disease, cancer and 
violence. They can also serve to measure the impact on 
mortality of interventions, such as opioid substitution 
treatment, and they give information about changes in the 
risks of death, such as those related to ageing. Many 
countries affiliated to the EMCDDA report insights from 
such studies (EMCDDA, 2011, 2015), but their use could be 
expanded to include the remaining countries.
Availability of cohorts and reports of information from 
cohort studies listed in the present paper and in the 
2015 EMCDDA study
Relevant cohort study
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overdoses. Reducing these deaths therefore remains 
a major challenge for public health policy worldwide and in 
Europe, as highlighted by the recent European data on 
drug-induced deaths presented above.
In addition, deaths from a number of other causes, such as 
those related to HIV or hepatitis C acquired through unsafe 
injection practices, are indirectly attributed to drug use. 
Taken all together, mortality directly or indirectly attributed 
to the use of illicit drugs is a considerable contributor to 
avoidable and premature deaths among adults worldwide. 
In many European countries, it accounts for a considerable 
number of years of life lost.
Crude drug-related mortality rates, excess mortality of 
high-risk drug users compared with the general population of 
the same age and sex, survival, and the most frequent 
causes of death among high-risk drug users are detailed 
below. The discussion is informed by new analyses of cohort 
studies presented by experts from Poland, Latvia, Austria 
and Estonia, in combination with findings from cohort studies 
that have been conducted in Europe over the past decade 
and discussed in previous publications (see figure in the box 
‘Monitoring overall mortality’, page 13, and the Appendix).
l Crude mortality rates
The majority of cohort studies reviewed show a crude 
mortality rate among enrolled high-risk drug users in the 
range of 10 to almost 30 deaths per 1 000 person-years 
(EMCDDA, 2011, 2015; Giraudon et al., 2012). Findings 
from Poland were presented, based on a cohort study that 
followed up 42 700 persons (346 735 person-years) 
between 2000 and 2016 (Appendix). A total of 5 489 
deaths (13 %) were reported over the study period, 
corresponding to a crude mortality rate of 15.8 per 1 000 
person-years.
Overdoses typically account for between one third and half 
of the deaths among high-risk drug users (EMCDDA, 
2015). An important limitation of some cohort studies is 
the fact that causes of death are sometimes unavailable, 
or non-specifically coded. This may result in an 
underestimation of the true proportion of deaths caused 
by overdose. In recent results from the Polish cohort study, 
5 % of the deaths are classified as drug-related, but many 
others are classified in ways that may suggest 
a mislabelling of overdoses; for example, some of those 
coded as related to ‘cardiovascular disease’, but also some 
that are recorded as ‘unclassified’, ‘other classified’ or 
‘self-harm’ (Figure 13).
FIGURE 13



















Source: Janusz Sierosławski, DRD meeting.
Crude mortality rate: a measure of the number of 
deaths in a population, scaled to the size of that 
population, per unit time. It is typically expressed as 
deaths per 100 or per 1 000 individuals per year.
High-risk drug use: injecting drug use or long-duration/
regular use of opioids, cocaine and/or amphetamines.
Person-years: an estimate of the actual time at risk, in 
years, that all study participants contributed to the 
study.
Standardised mortality rate: a crude mortality rate that 
is adjusted for differences in age and sex composition 
between the study population (e.g. high-risk drug users) 
and a standard population.
Standardised mortality ratio: a measure of the excess 
risk of mortality of a specific group compared with their 
peers of the same age and gender in the general 
population.
Survival analysis: a form of time-to-event analysis in 
which the event considered is the death of participants, 
and time is measured from the participants’ enrolment 
in the study.
Definitions used in mortality cohort studies
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l Excess mortality and premature deaths
Data suggest that high-risk drug users have a three to 20 
times higher mortality risk than their peers of the same age 
and gender in the general population (three to seven times 
higher overall in the studies reported in 2018; Appendix). 
The excess risk of overdose mortality in particular is much 
higher (see Latvian study below).
Survival analysis provides an insight into how the risk of 
death accumulates over time and how the lives of the 
participants enrolled in a study are lost prematurely. In the 
Polish cohort study, almost one tenth of the participants 
died within the first 5 to 8 years of follow-up, and one fifth 
died within 13 to 15 years (Figure 14). In this study, the 
mortality risk was relatively constant over time, following 
the enrolment of participants.
In Austria, a large cohort study enrolled more than 25 000 
patients receiving opioid substitution treatment, from 
January 2002 to December 2016. Most participants were 
enrolled in their early twenties. Over 1 500 deaths were 
recorded, more than a third of which were coded in the 
special mortality register as directly related to drug use. 
The crude mortality rate of participants was 7.7/1 000 
person-years and the standard mortality ratio was 4.5. This 
means that the mortality risk of those who have started 
FIGURE 14
Survival functions for males and females in psychiatric 
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FIGURE 15
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Mortality cohort studies can be used to cross-validate 
national statistics on overdose. To get an accurate and 
valid measure of the real burden of drug overdose, an 
assessment of its possible underestimation is 
important. This can be done, for example, through 
capture-recapture techniques (Janssen, 2011). The 
EMCDDA developed a model for opioid multi-indicator 
analysis to explore possible opioid overdose 
underestimations. The model is based on the 
assumption that the number of fatal opioid overdoses is 
proportional to the size of the population at risk.
To implement the multi-indicator triangulation, several 
indicators are combined, separately for each country: 
high-risk opioid users prevalence, number of clients in 
opioid substitution treatment (OST) proportion of 
injectors and reported number of fatal opioid overdoses. 
Some other indicators are not included in the current 
model (e.g. age, polydrug use, market indicators and 
other protective interventions in addition to OST, such 
as take-home naloxone or safe consumption facilities).
Three subgroups of high-risk opioid users are defined 
based on their level of risk of overdose death; those in 
OST (low risk), those not in OST and not injecting drugs 
(medium risk), and those injecting drugs and not in OST 
(high risk). The OST group is further divided into 
treatment ‘predominantly based on methadone’ and 
‘predominantly based on buprenorphine’. The expected 
mortality rates for each group are derived from scientific 
literature, and where possible from national cohort 
studies. The expected number of opioid-induced deaths 
is computed for each subgroup and added up to 
determine the expected number of fatal opioid 
overdoses.
The methodology was piloted in two countries: Latvia 
and Bulgaria.
In Latvia, preliminary estimates of opioid-induced 
deaths were obtained with different methods and 
sources. These estimates varied substantially, but in all 
cases strongly suggested an underestimation. Possible 
reasons for it include difficulty in identifying novel 
synthetic opioids; limited number of full post-mortem 
investigations; unspecific and ill-defined causes of 
deaths; and lack of liaison between forensic sources and 
the general mortality register.
In Bulgaria, findings strongly suggested an 
underestimation. Possible reasons include limited 
analytical capacity, limited number of toxicologists, 
limited use of information from police and forensic 
laboratory sources in death certification, and possible 
overestimation of the number of high-risk opioid users 
(inflating the estimated number of opioid deaths).
Preliminary recommendations included enhancing the 
descriptive epidemiology of overdoses in terms of time, 
place and persons; considering a capture-recapture 
study; refining high-risk opioid use estimates; mapping 
the responses in place; and cross-validating fatal 
overdose data with drug-related emergencies, treatment 
and market data.
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opioid substitution treatment was 4.5 times that of the 
general population with the same age and gender 
distribution. It also suggests that the mortality of people 
receiving opioid substitution treatment in Austria is lower 
than in other countries (see Appendix).
In Estonia, HIV infection and drug use are strongly 
interlinked. A retrospective register-based cohort study 
that enrolled almost 7 900 patients living with HIV, and 
linked healthcare data from national databases with the 
Estonian Causes of Death Registry, provides interesting 
insights into drug-related deaths. It must be borne in mind 
that as the enrolment criteria in this study (patients living 
with HIV) differ from those in many other studies (patients 
enrolled in drug treatment), the results are not readily 
comparable.
By the end of 2017, the study showed that drug overdose 
was the most frequent cause of death (29 %; Figure 15). 
The overall median age at death was 33 years, but younger 
for those who died of overdose (31 years) and suicide 
(31 years), and higher for those who died of cardiovascular 
disease (45 years) or non-HIV-related cancer (51 years). 
The mortality rates observed in this study were very high 
(31 deaths per 1 000 person-years; Appendix). In Estonia, 
almost half (47 %) of the fatal overdoses reported in 2017 
occurred in people who lived with HIV, underlining how 
overdose risk, injecting drug use and HIV are closely 
interlinked. These findings are important to inform the 
provision of responses appropriate to the needs and risks 
of this population (Lemsalu et al., 2018).
In Latvia, the pilot study mentioned in the box on multi-
indicator analysis (page 16) was in part informed by the 
recent longitudinal cohort study conducted from January 
2013 to December 2017, which enrolled 2 315 high-risk 
drug users (primarily opioid/stimulant and synthetic 
cannabinoid users) aged 15- to 49-years-old. The mean 
age at enrolment was 29 years, and eight out of 10 
participants were male. There were 182 deaths reported, 
more than a third (37 %) of which were attributed to 
external causes, and almost a third (29 %) to disease of 
the circulatory system (Figure 16). The analysis of cause of 
death reported in death certificates revealed that only 15 
(8 %) of the 182 deaths were coded as overdose in the 
general mortality register. This small number suggests that 
some of the 67 deaths attributed to external causes may 
have been unrecognised and miscoded overdoses. There 
could be other unrecognised overdoses, for example 
among those reported as due to ‘disease of the circulatory 
system’ (53 fatalities). Therefore, the 15 recorded 
overdoses can be taken as a minimum figure, as it is likely 
that only some of the overdoses are flagged and 
retrievable in national mortality statistics.
l Responding to drug-related deaths
Reducing overdose morbidity and mortality is a major 
public health challenge in Europe. A broader public health 
response in this area aims to reduce vulnerability among 
high-risk drug users, especially by removing barriers and 
making services accessible, and by empowering them to 
take fewer risks (EMCDDA, 2017c, 2018c). In recent years, 
some European countries (e.g. Norway and Sweden) have 
developed national overdose prevention strategies, and 
specific enquiries into drug overdose have been conducted 
in the United Kingdom (ONS, 2018).
This section concerns only drug consumption rooms and 
take-home naloxone programmes, for which national 
updates were presented and discussed at the expert 
meeting, including challenges in measuring their impact. 
An overview of other responses to drug-related deaths, 
including retention in opioid substitution treatment, which 
has a strong protective effect, is available in the European 
guide Health and Social Responses to Drug Problems 
(EMCDDA, 2017c) and at the EMCDDA’s online Best 
Practice Portal.
l Drug consumption rooms
Drug consumption rooms are professionally supervised 
healthcare facilities where people can use drugs in safer 
and more hygienic conditions (Hedrich et al., 2010). Drug 
consumption rooms seek to attract hard-to-reach 
populations of people who use drugs, especially 
FIGURE 16
Causes of deaths among high-risk drug users enrolled in 















Source: Diāna Vanaga, presented by Linda Veisberga, adapted by the 
EMCDDA.
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marginalised groups and those who use drugs on the 
streets or in other risky settings. They aim to reduce 
morbidity and mortality by providing a safe environment, 
training clients in safer drug use, and promoting access to 
social, health and drug treatment facilities (Hedrich et al., 
2015). Drug consumption rooms also seek to reduce drug 
use in public places and improve public amenity in areas 
surrounding urban drug markets. Six EU countries 
(Belgium, Denmark, France, Luxembourg, Netherlands, 
Spain) and Norway, as well as Switzerland, Canada and 
Australia, have established drug consumption rooms as 
part of an integrated response to specific local problems.
Studies on the effectiveness and impact of safer injecting 
facilities suggest that drug consumption rooms reach the 
most marginalised injecting drug users, facilitate access to 
healthcare services, are effective in reducing self-reported 
high-risk behaviour, promote safer use practices and may 
therefore have a protective effect regarding overdose-
related morbidity and mortality. They have not been shown 
to increase drug use or frequency of injecting among their 
clients, and do not result in higher rates of local drug-
related crime, but are likely to be effective only when 
integrated into a wider public policy framework and based 
on consensus, support and active cooperation among 
local key actors (healthcare providers, police, local 
authorities and consumers themselves). For an overview 
on the research on drug consumption rooms, see 
Belackova and Salmon (2017), Belackova et al. (2019), 
Hedrich and Hartnoll (2015) and Kennedy et al. (2017). At 
the meeting, experts from three countries provided 
updates on the introduction or expansion of drug 
consumption rooms in their jurisdictions. In France, during 
the first 12 months of a pilot project in Paris and 
Strasbourg, more than 1 000 clients used the drug 
consumption rooms, and more than 200 consumptions 
were supervised each day. In Finland, in 2018 the Helsinki 
city council agreed to establish a drug consumption room. 
In Canada, 20 such facilities, operating in 11 cities, were 
recently established in response to the opioid deaths 
epidemic in the country.
l Take-home naloxone programmes
Naloxone is an opioid antagonist medication used 
worldwide in emergency medicine to reverse respiratory 
depression caused by opioid overdose. Take-home 
naloxone (THN) programmes aim to prevent opioid 
overdose deaths by providing the medication to potential 
bystanders (e.g. opioid users, their peers and families) and 
training them to recognise an overdose and intervene 
using naloxone. The medication is available as an 
injectable solution in ampoules or pre-filled syringes and, 
more recently, as an intranasal spray’.
In Europe, THN programmes of local, regional or national 
scope are currently running in 11 countries. In Italy, where 
the medication is available without prescription, service 
providers can distribute it to potential bystanders 
(EMCDDA, 2018c; Figure 17).
In Norway, the implementation of the national THN 
programme is expanding; the medication and related 
training is now available in more than 30 municipalities, 
and a newly approved nasal naloxone spray is in use since 
June 2018. The programme is supported by government 
funding, involves user groups and other key stakeholders, 
and is carried out in collaboration with the public health 
infrastructure, which allows a broad reach and rapid 
expansion. More than 1 200 trainers have been trained, 
and more than 6 000 naloxone kits were distributed 
between 2014 and 2017 (including more than 2 500 in 
2017 alone), as well as a provisional number of around 
4 000 for 2018, adding up to more than 10 000 kits 
distributed from 2014 to 2018 in Norway. An e-health 
training programme and video are also available.
The Estonian THN programme started in 2013 and is 
implemented by six service providers in the counties of 
Harju and East Viru. By the end of 2017, more than 2 000 
people had been trained and 2 600 naloxone kits had been 
FIGURE 17
Availability and scope of take-home naloxone programmes 
in Europe, 2018
Availability and scope
Local or regionalNational Under discussion
Not available
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distributed. The programme was extended to prison 
medical departments in 2015: around 140 prisoners were 
trained in the use of naloxone and given pre-filled naloxone 
syringes upon release, in order to reduce the risk of opioid 
overdose death.
In 2017, the Swedish government ordered the National 
Board of Health and Welfare and the Swedish Medicinal 
Products Agency to increase the availability of naloxone in 
pre-hospital settings. This resulted in national guidelines 
for naloxone programmes, which allow nurses to prescribe 
and hand out naloxone to patients at risk of an opioid 
overdose. A national information package on overdose 
risks and overdose treatment has also been developed. 
There are two versions, one directed at those using 
opioids, and their relatives, and one directed at 
professionals.
With increasing implementation of THN programmes, the 
evidence base for their effectiveness is growing (Bird et al., 
2016; Espelt et al., 2017; Langham et al., 2018). While 
studies confirm that naloxone saves lives, they also 
caution against taking THN programmes as a panacea. The 
extent of impact of THN is likely to vary from country to 
country. Mortality impact studies will be critical to ensuring 
the future sustainability and development of THN 
programmes.
l  The way forward: exploring complementary sources
In addition to taking stock of the epidemiological situation 
and current responses to drug overdose in Europe, the 
annual expert meeting also facilitated the sharing of 
monitoring experiences with additional sources of 
information: open source information and hospital 
emergency settings. These sources provide data that can 
be triangulated with other sources in order to detect 
changing patterns and the emergence of new substances. 
They also provide data in a more timely manner, potentially 
contributing to earlier identification of problems.
l Open source information monitoring
GeOverdose.it, a private initiative, is an Italian database 
linked to a geographical information system, interfaced 
with a website, that provides a visual mapping of fatal and 
non-fatal drug overdoses in Italy. The database is fed by 
search engines scanning online national and local 
newspapers, and is continuously updated by professionals 
working in public treatment services (Figure 18). This 
project is linked to ‘NeverDose’, an experimental 
programme aiming to prevent drug overdose. Both 
programmes form a concrete attempt to use new 
technologies and the internet for the prevention and 
reduction of drug-related harms. An important benefit of 
GeOverdose.it, in addition to providing an early warning of 
FIGURE 18
Screenshot of the GeOverdose website, Italy
Source: https://www.geoverdose.it/
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clusters of overdose, is that the information can be 
triangulated with other sources, such as drug seizures, 
wastewater analysis, hospital data and drug treatment 
data, to detect signals of changing health threats. 
GeOverdose.it monitoring shows that the overwhelming 
majority of overdosed drug users were alone at the time of 
consumption. This initiative aims to raise awareness 
among local communities for prompt integrated 
interventions.
l  Hospital emergencies: monitoring acute intoxications
In France, a national system of surveillance based on 
emergency departments was set up to identify situations 
requiring a rapid public health response. Data collection is 
based on direct extraction from patients’ electronic 
medical records compiled during their visit to the 
emergency room. Data include main and associated 
diagnoses coded with the International Classification of 
Diseases 10th Revision (ICD-10), and destination of the 
patient after the emergency visit. Similarly to other 
countries in Europe, the surveillance system shows that 
drug-related hospital emergency visits concern mainly 
a young adult male population. The most common 
substances involved in acute toxicity presentations vary by 
location and year, and there are marked differences in the 
demographics of the patients, depending on the 
substances used: a third of the acute intoxications related 
to opioids occur among patients aged 45 years and more, 
and over half of the intoxications related to cannabis occur 
in patients aged less than 25 years (Figure 19). This 
information source has the added advantage of timeliness 
and capacity to contribute to early warnings, compared 
with the less timely data from national mortality statistics.
l Conclusions
This publication provides an update on drug-related 
deaths in the EU Member States, Norway and Turkey, and 
of the state of play of the monitoring of this public health 
issue by the Reitox national focal points and national 
experts. The European monitoring of drug-related deaths 
is based on two pillars: the monitoring of drug-induced 
deaths or overdoses, and the monitoring of the overall 
mortality risk among people using drugs, particularly those 
who are high-risk drug users. From both perspectives, 
according to the most recent data presented here, there 
are reasons for concern.
Thousands of drug-induced deaths are reported in Europe 
every year. These deaths are preventable and premature. 
Opioids, mainly heroin, continue to take the highest toll, 
but there are worrying trends highlighted by forensic 
toxicology evidence in some parts of Europe. These are 
related to changes in the drug market and the availability of 
new opioids (including fentanyl analogues), prescription 
opioids, other medicines such as new benzodiazepines, 
and cocaine in both powder and crack form. There are also 
challenges arising from the changing populations at risk, in 
particular the continued ageing of opioid users in west 
European countries.
The updates presented in this report shed light on 
important public health challenges faced by European 
policymakers and stakeholders, with regard to prevention, 
risk assessment, harm reduction and drug treatment. 
Overdose is a multifaceted problem (EMCDDA, 2017b) 
requiring a combination of responses tailored to the 
particular circumstances of at-risk populations. Beyond 
overdose, other causes of morbidity and mortality 
disproportionally affect people using drugs. Reducing 
drug-related mortality associated with somatic causes, 
such as HIV/AIDS, hepatitis and liver failure, and also 
alcohol-related problems, suicide and violence, will 
demand additional responses. Cohort studies contribute 
to a better understanding of drug-related mortality in 
Europe, including the impact of particular responses. The 
implementation of cohort and linkage studies in EU 
Member States that have not yet done so requires 
FIGURE 19
Distribution of drug-related hospital emergency visits in 
France, by age group and substances in 2015












Source: OSCOUR network (Santé Publique France), processed by the 
French Observatory for Drugs and Drug Addiction (OFDT), presented by 
Anne-Claire Brisacier at the DRD expert meeting.
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relatively little investment and may be as simple as linking 
treatment data with mortality registers.
There is a need to improve the epidemiology of drug-
related deaths in order to get more accurate and 
informative figures. Doing so includes strengthening the 
completeness and comparability of information available 
from forensic toxicology sources, if the exact drivers and 
triggers of deaths and outbreaks are to be understood and 
tackled. Investing in enhanced monitoring, preparedness 
and responses in Europe is crucial, particularly against the 
backdrop of the drug overdose crises currently 
experienced by the United States and Canada.
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GETTING IN TOUCH WITH THE EU
In person
All over the European Union there are hundreds of Europe 
Direct information centres. You can find the address of the 
centre nearest you at: http://europa.eu/contact
On the phone or by e-mail
Europe Direct is a service that answers your questions about 
the European Union. You can contact this service 
•  by freephone: 00 800 6 7 8 9 10 11  
(certain operators may charge for these calls) 
•  at the following standard number: +32 22999696 or
•  by electronic mail via: http://europa.eu/contact
FINDING INFORMATION ABOUT THE EU
Online
Information about the European Union in all the official 
languages of the EU is available on the Europa website at: 
http://europa.eu  
EU publications
You can download or order free and priced EU publications 
from EU Bookshop at: http://bookshop.europa.eu.  
Multiple copies of free publications may be obtained by 
contacting Europe Direct or your local information centre  
(see http://europa.eu/contact)
EU law and related documents
For access to legal information from the EU, including all 
EU law since 1951 in all the official language versions, go to 
EUR-Lex at: http://eur-lex.europa.eu
Open data from the EU
The EU Open Data Portal (http://data.europa.eu/euodp/en/data)  
provides access to datasets from the EU. Data can be 
downloaded and reused for free, both for commercial and  
non-commercial purposes.
About this publication
Rapid Communications bring you the latest findings 
and discussions in key areas in the drugs field. This 
publication provides an update on drug-related deaths 
in Europe, presenting and analysing the latest data and 
trends in drug-induced deaths and overall mortality 
among high-risk drug users in the European Union and 
beyond. It draws on contributions from specialists 
representing more than 40 countries at the latest 
meeting of the EMCDDA expert network on drug-
related deaths in November 2018 as well as 
information provided by European countries in the 
annual reporting exercise.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For over 20 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
